Correction: Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
Mev Dominguez–Valentin(Norwegian Cancer Society), Steven Gallinger(Ontario Institute for Cancer Research), Magnus von Knebel Doeberitz(Heidelberg University), Francisco López‐Köstner(Clínica Las Condes), Annika Lindblom(Karolinska University Hospital), Stefan Aretz(University of Bonn), John L. Hopper(The University of Melbourne), Toni T. Seppälä(University of Helsinki), Markus Loeffler(Leipzig University), Karl Heinimann(University Hospital of Basel), Robert Hüneburg(University Hospital Bonn), Laura Renkonen‐Sinisalo(University of Helsinki), Noralane M. Lindor(Mayo Clinic in Arizona), John Burn(Newcastle University), Nils Rahner(University of Bonn), Sigve Nakken(Oslo University Hospital), Giulia Martina Cavestro(University of Parma), Christoph Engel(University Hospital Leipzig), Gabriel Capellá(Institut Català d'Oncologia), Lucio Bertario(European Institute of Oncology), Julian R. Sampson(Cardiff University), Francesc Balaguer(Universitat de Barcelona), Robert W. Haile(University of Southern California), Heike Görgens(Technische Universität Dresden), Wouter H. de Vos tot Nederveen Cappel(Isala), Elke Holinski‐Feder(Garvan Institute of Medical Research), Nathan Gluck(Tel Aviv University), Marc S. Greenblatt(University of Vermont), Monika Morak(University of Helsinki), Aung Ko Win(The Royal Melbourne Hospital), Inge Bernstein(Aalborg University Hospital), John‐Paul Plazzer(University of Vermont), Stefanie Holzapfel(University of Bonn), Lone Sunde(Aalborg University Hospital), Verena Steinke‐Lange(University of Cambridge), Sanne W. ten Broeke(Leiden University Medical Center), Rolf H. Sijmons(University Medical Center Groningen), Kirsi Pylvänäinen(Central Finland Health Care District), Deepak Vangala(Universitätsklinikum Knappschaftskrankenhaus Bochum), Eivind Hovig(Oslo University Hospital), Adriana Della Valle(Hospital Central de las Fuerzas Armadas), D. Gareth Evans(Manchester Academic Health Science Centre), Carlos Vaccaro(Hospital Italiano de Buenos Aires), Mark A. Jenkins(The University of Melbourne), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hans K. Schackert(Technische Universität Dresden), Huw Thomas(St Mark's Hospital), Lior H. Katz(Sheba Medical Center), Maria Grazia Tibiletti(University of Insubria), Reinhard Büttner(University Hospital Cologne)
Cited by 12
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k